Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIANCE: GP Initiation of Insulin Glargine in T2DM
NCT00950534Phase 4Terminated
- Sponsor
- Sanofi
- Start
- Jul 2009
- Primary completion
- Aug 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Insulin Glargine + OAD with Standard of Care (OADs) (2 arms). Primary endpoint: Percentage of patients achieving glycosylated haemoglobin (HbA1c) levels <= 7.0% at 24 weeks. Started Jul 2009; status: terminated.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00950534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00950534.